<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048514</url>
  </required_header>
  <id_info>
    <org_study_id>N09-01</org_study_id>
    <nct_id>NCT02048514</nct_id>
  </id_info>
  <brief_title>The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms</brief_title>
  <official_title>The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endologix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endologix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and device performance of the&#xD;
      Nellix® EndoVascular Aneurysm Sealing System (Nellix System) for the treatment of infrarenal&#xD;
      abdominal aortic aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, multi-country prospective, single-arm, non-randomized clinical trial.&#xD;
      The comparative control arm is a combination of patient data drawn from the abdominal aortic&#xD;
      aneurysms (AAA) open surgical control arms of four commercially approved AAA devices as part&#xD;
      of the Society of Vascular Surgeons. Patients enrolled in this study will be pre-screened and&#xD;
      have a diagnosis of an infrarenal AAA with or without the need for treatment of iliac artery&#xD;
      aneurysm, are candidates for endovascular repair, and meet the eligibility criteria. Patients&#xD;
      enrolled in the study will participate in follow-up visits 31 days, 6 months and at 1 year&#xD;
      following the index procedure. At the follow-up visits there will be a clinical assessment,&#xD;
      blood collection, and abdominal CT imaging of the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety- Number of Major Adverse Events</measure>
    <time_frame>30 day</time_frame>
    <description>The primary safety endpoint is defined as the incidence of Major Adverse Events (MAE) through 30 days after the index procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Performance</measure>
    <time_frame>30 days</time_frame>
    <description>The primary performance endpoint is technical success defined as successful delivery and deployment of the device and freedom from open surgical conversion at 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Any death occurring during the study period, regardless of cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Abdominal Aortic Aneurysms</condition>
  <arm_group>
    <arm_group_label>Nellix Aneurysm Sealing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Nellix® EndoVascular Aneurysm Sealing System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Nellix® EndoVascular Aneurysm Sealing System</intervention_name>
    <arm_group_label>Nellix Aneurysm Sealing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Informed consent form understood and signed and patient agrees to all follow-up visits&#xD;
&#xD;
          -  Is able and willing to comply with clinical follow-up requirements for one year&#xD;
&#xD;
          -  Is able and willing to undergo Contrast-Enhanced Spiral CT scans&#xD;
&#xD;
          -  Is a candidate for endovascular repair of an infrarenal aortic aneurysm with or&#xD;
             without an iliac aneurysm with at least one of the following;&#xD;
&#xD;
               1. aneurysm ≥ 4.5 cm in diameter, or&#xD;
&#xD;
               2. aneurysm is twice the diameter of the normal infrarenal aorta, or&#xD;
&#xD;
               3. aneurysm is growing at a rate of ≥ 10 % per year&#xD;
&#xD;
          -  Non-aneurysmal aortic neck length ≥ 5mm below the most inferior renal artery&#xD;
&#xD;
          -  Proximal aortic neck diameter between 16 and 36mm&#xD;
&#xD;
          -  Aortic neck angulation to the sac ≤ 60&#xD;
&#xD;
          -  Common iliac artery diameter 8 to 35mm bilaterally&#xD;
&#xD;
          -  Aneurysm blood lumen diameter ≤ 60mm&#xD;
&#xD;
          -  Iliac and femoral arteries suitable for endovascular access with the Nellix System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy ≤ 1 year&#xD;
&#xD;
          -  Dissecting, ruptured, or leaking aneurysm (blood outside the aorta), has sustained&#xD;
             recent trauma, is symptomatic, or is non-degenerative&#xD;
&#xD;
          -  Aneurysm is thoraco-abdominal, suprarenal and/or mycotic&#xD;
&#xD;
          -  Thoracic aneurysm ≥ 4.5cm in diameter&#xD;
&#xD;
          -  AAA requires treatment that would result in bilateral occlusion of the internal iliac&#xD;
             arteries&#xD;
&#xD;
          -  Presence of mural thrombus &gt; 50% circumferentially in aortic neck&#xD;
&#xD;
          -  Iliac aneurysm blood lumen diameter &gt; 35mm&#xD;
&#xD;
          -  Active infection, vasculitis, or systemic connective tissue disease (e.g., Rheumatoid&#xD;
             arthritis, scleroderma, Marfan's syndrome, Ehlers-Danlos disease) at time of procedure&#xD;
&#xD;
          -  History of prior treatment of abdominal aortic or iliac artery aneurysm disease&#xD;
&#xD;
          -  Femoral or iliac artery occlusive disease such that device delivery is not possible&#xD;
&#xD;
          -  Vascular access for delivery of device requires placement of vascular conduit or is&#xD;
             through an established vascular graft&#xD;
&#xD;
          -  Receiving dialysis&#xD;
&#xD;
          -  History of hypercoagulability&#xD;
&#xD;
          -  Allergy to IV contrast&#xD;
&#xD;
          -  Serum creatinine level &gt;2.0 mg/dL (or equivalent)&#xD;
&#xD;
          -  Patient is pregnant or nursing&#xD;
&#xD;
          -  Patient is currently enrolled in an investigational drug or device trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro Medico de Cali</name>
      <address>
        <city>Cali</city>
        <zip>24-157</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Stradins University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1007</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Clinicas Y Urologica Tomanaco</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Latvia</country>
    <country>New Zealand</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Aneurysm, Abdominal</keyword>
  <keyword>Endovascular Procedures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

